This is a pilot study examining the effect of dietary supplements that contain soy products.
The purpose of this study to find out if soy supplementation can help to reduce the storage
of a certain kind of fat on the body, visceral fat. Visceral fat is fat found deep in the
abdomen; it has the potential to increase the risk of certain health problems.
Obesity is a leading risk factor for many chronic diseases in the USA. Abdominal fat,
specifically visceral fat is metabolically active and can be detrimental to health.
Abdominal obesity is especially high in postmenopausal women (prevalence rates 50- 70%) in
whom estrogen deficiency may lead to accumulation of excess visceral fat. Although estrogen
replacement therapy is effective in preventing visceral fat accumulation, its adverse
effects warrant a search for a safer phytochemical that exerts estrogenic properties. Soy,
containing isoflavones (estrogen-like compounds), is a promising dietary component in
reducing abdominal obesity in menopausal women. The favorable effects of isoflavones were
already demonstrated in animal studies.The effects of soy compounds as a dietary component
in preventing and reducing abdominal obesity and its associated metabolic abnormalities will
be examined among menopausal Women. We will use quantitative magnetic resonance
spectroscopy/imaging (qMRS/I) to determine dose and effects of soy supplementation for
preventing and treating abdominal adiposity. The results from this study will shed light on
the application of soy as a novel dietary approach in preventing and managing abdominal
obesity among peri- and early menopausal women.
1. Between the ages of 45 and 60
2. experiencing irregular menses along with one or more other symptoms of menopause
including: vaginal dryness, difficulty sleeping, hot flashes, mood changes, increased
abdominal/belly fat, or with cessation of menstrual cycle for no more than three
3. having a BMI greater than 25
4. Waist circumference greater than 88 cm
5. having the ability to understand study procedures and to comply with them for the
entire length of the study.
1. Have ever been diagnosed with cancer
2. Have tumors in the reproductive system
3. Allergies to soy or milk protein
4. Have known metabolic disorders that may affect body weight and body composition
(e.g., hypercortisolism and hypothyroidism, non-alcoholic fatty liver disease)
5. Are receiving hormone replacement therapy or estrogen-like remedy
6. Are taking medications (e.g., thyroid, cortisol/cortisone, ephedra, thermogenics,
etc) within 30 days prior to the start of the study.
7. Are emotional or uncontrolled eaters as measured by a brief screening tool
Three-Factor Eating Questionnaire (TFEQ), i.e., 3 "yes" to the three emotional eating
questions or 2 "yes" to the 2 uncontrolled eating questions.